Post hoc findings in this cohort, specifically participants with severe uncontrolled asthma, baseline FEV1 reversibility ≥ 12%, no regular OCS use at entry, and elevated DPP-4 or periostin, showed that 300 mg of tralokinumab administered subcutaneously every two weeks yielded improvements in lung function, exacerbation frequency, symptom control, and quality of life [186]. The gene discussed is DPP4; the disease is asthma.